Neurocrine Biosciences (NBIX)
Develops and commercializes neuroscience and rare-disease medicines led by INGREZZA.
$142.58
vs last close−1.38 (−0.96%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 499 | 515 | 515 | 590 | 622 | 628 | 573 | 688 | 795 | 806 | 815 | 959 |
| Cost of revenue | 11 | 9 | 8 | 9 | 8 | 9 | 9 | 11 | 14 | 18 | 14 | 23 |
| Gross profit | 488 | 507 | 508 | 581 | 614 | 618 | 563 | 676 | 781 | 788 | 801 | 936 |
| 346 | 356 | 409 | 436 | 430 | 476 | 540 | 531 | 542 | 577 | 615 | 783 | |
| Research & development | 142 | 138 | 159 | 191 | 195 | 186 | 263 | 244 | 250 | 258 | 296 | 327 |
| Selling, general & administrative | 204 | 219 | 243 | 242 | 234 | 288 | 277 | 286 | 292 | 302 | 319 | 440 |
| Other expenses | 0 | 0 | 6 | 3 | 1 | 3 | 0 | 0 | 0 | 17 | 0 | 16 |
| Operating income | 141 | 150 | 99 | 145 | 184 | 142 | 24 | 146 | 239 | 211 | 186 | 153 |
| −26 | 48 | −65 | −47 | 7 | 21 | −9 | 14 | 53 | 29 | 61 | 9 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 21 | 22 | −43 | 28 | 0 |
| Interest expense | 1 | 1 | 1 | 50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Other non-operating income | 0 | −49 | −6 | −3 | −1 | −33 | 0 | −14 | −53 | −17 | 0 | −12 |
| Income before tax | 116 | 198 | 35 | 99 | 190 | 163 | 15 | 160 | 292 | 239 | 247 | 162 |
| Income tax expense | 33 | 51 | −9 | 34 | 61 | 60 | 7 | 52 | 82 | 86 | 49 | 18 |
| Net income from continuing operations | 83 | 148 | 43 | 65 | 130 | 103 | 8 | 108 | 210 | 154 | 198 | 144 |
| Net income | 83 | 148 | 43 | 65 | 130 | 103 | 8 | 108 | 210 | 154 | 198 | 144 |
| EPS, basic | $0.85 | $1.50 | $0.43 | $0.64 | $1.28 | $1.03 | $0.08 | $1.09 | $2.11 | $1.54 | $1.97 | $1.43 |
| EPS, diluted | $0.82 | $1.44 | $0.42 | $0.63 | $1.24 | $1.00 | $0.08 | $1.06 | $2.04 | $1.48 | $1.91 | $1.39 |
| Weighted average shares, basic | 98 | 98 | 100 | 101 | 101 | 100 | 100 | 99 | 99 | 100 | 101 | 101 |
| Weighted average shares, diluted | 101 | 102 | 104 | 104 | 104 | 103 | 103 | 101 | 103 | 103 | 103 | 104 |
| EBITDA | 147 | 205 | 112 | 155 | 191 | 182 | 31 | 167 | 300 | 235 | 193 | 190 |
| Depreciation & amortization | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 7 | 8 | 8 | 7 | 25 |
| EBIT | 141 | 199 | 105 | 148 | 185 | 175 | 24 | 160 | 292 | 228 | 186 | 165 |